Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Linda B. Ford"'
Publikováno v:
Pediatric Asthma, Allergy & Immunology; December 2003, Vol. 16 Issue: 4 p325-329, 5p
Autor:
Helene Goulaouic, Michael E. Wechsler, Andreas Jessel, George D. Yancopoulos, Elliot Israel, Ian D. Pavord, Jorge Maspero, Nikhil Amin, Linda B. Ford, Klaus F. Rabe, Marcella Ruddy, Michael C Nivens, David M. Weinreich, Chih-Chi Hu, Renata Martincova, Raolat M Abdulai
Publikováno v:
New England Journal of Medicine. 385:1656-1668
Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody against the upstream alarmin interleukin-33. The efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ead5dcc2e92090216c860a90da7e8062
https://doi.org/10.1056/nejmoa2024257
https://doi.org/10.1056/nejmoa2024257
Autor:
Yi Zhang, David Langton, Michael E. Wechsler, Arnaud Bourdin, A.H. Khan, Jorge Maspero, Ian D. Pavord, Henrik Watz, Megan Hardin, Xuezhou Mao, Linda B. Ford, Christian Domingo, Alberto Papi, Nikhil Amin
Publikováno v:
Diagnostics and monitoring of asthma and co-morbidities.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdfa87e04e462b4f66c077b8a3610675
https://doi.org/10.1136/thorax-2021-btsabstracts.158
https://doi.org/10.1136/thorax-2021-btsabstracts.158
Autor:
Yuji Tohda, Yi Zhang, Elizabeth Laws, Alberto Papi, Linda B. Ford, Natalia M Nenasheva, Michael E. Wechsler, Ian D. Pavord, Leda Mannent, Upender Kapoor, Nikhil Amin, Asif H. Khan, Henrik Watz, Paul Rowe, Jorge Maspero, David Langton, Hae-Sim Park, Mario Castro, Marcella Ruddy, Arnaud Bourdin, Megan Hardin, Xuezhou Mao, Faisal A. Khokhar, Christian Domingo, Guido Cardona, Yamo Deniz, Kenneth R. Chapman
Publikováno v:
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine, Elsevier, 2021, ⟨10.1016/S2213-2600(21)00322-2⟩
The Lancet Respiratory Medicine, Elsevier, 2021, ⟨10.1016/S2213-2600(21)00322-2⟩
Summary Background Clinical trials have shown treatment benefits of dupilumab in patients with uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::828a5b08dc17d4200d31d0d5511c4a7f
https://hal.archives-ouvertes.fr/hal-03363008
https://hal.archives-ouvertes.fr/hal-03363008
Autor:
G. Daniel Brooks, Athanasios Charalampopoulos, German D. Ramon, Regula Gehrig, Annika Saarto, Ellý Guđjohnsen, Susan K. Harry, Allison Crimmins, Despoina Vokou, Paul J. Beggs, Maira Bonini, Jae Won Oh, Lewis H. Ziska, Michel Thibaudon, Elena Severova, Starri Heiđmarsson, Athanasios Damialis, Dorota Myszkowska, Marijke Hendrickx, Gilles Oliver, László Makra, Nicolas Bruffaerts, Krista Sullivan, Kim Knowlton, Linda B Ford, Frances Coates
Publikováno v:
The Lancet Planetary Health, Vol 3, Iss 3, Pp e124-e131 (2019)
Lancet Planet Health 3, e124-e131 (2019)
Lancet Planet Health 3, e124-e131 (2019)
Summary Background Ongoing climate change might, through rising temperatures, alter allergenic pollen biology across the northern hemisphere. We aimed to analyse trends in pollen seasonality and pollen load and to establish whether there are specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3963abf9693a330f4e287b7cea03e65
https://doi.org/10.1016/s2542-5196(19)30015-4
https://doi.org/10.1016/s2542-5196(19)30015-4
Autor:
Jagadeesh Puvvula, Jill A. Poole, Sandra Gonzalez, Eleanor G. Rogan, Yeongjin Gwon, Andrew C. Rorie, Linda B. Ford, Jesse E. Bell
Publikováno v:
Environmental Epidemiology. 6:e225
Exposure to air pollutants is known to exacerbate asthma, with prior studies focused on associations between single pollutant exposure and asthma exacerbations. As air pollutants often exist as a complex mixture, there is a gap in understanding the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9a4534292c9a21aaf12787be51dbfdc
https://doi.org/10.1097/ee9.0000000000000225
https://doi.org/10.1097/ee9.0000000000000225
Autor:
Henrik Watz, David Langton, Jorge Maspero, Linda B. Ford, Alberto Papi, Nikhil Amin, Michael E. Wechsler, Arnaud Bourdin, Megan Hardin, Xuezhou Mao, Ian D. Pavord, Asif H. Khan, Christian Domingo, Yi Zhang
Publikováno v:
TP10. TP010 CLINICAL AND POPULATION-LEVEL STUDIES OF ASTHMA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0057010f647d915b9deaba028f227416
https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1452
https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1452
Autor:
Michael E. Wechsler, Faisal A. Khokhar, Arnaud Bourdin, Upender Kapoor, Christian Domingo, Yuji Tohda, Elizabeth Laws, Kenneth R. Chapman, Henrik Watz, Jorge Maspero, Megan Hardin, David Langton, Xuezhou Mao, Linda B. Ford, Hae-Sim Park, Alberto Papi, Ian D. Pavord, Leda Mannent, Nikhil Amin, Benjamin Ortiz, Marcella Ruddy, Michel Djandji
Publikováno v:
Allergy and immunology.
Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL‑4/IL‑13. The efficacy and safety of DPL in asthma have been demonstrated up to 52 wks in phase (P) 2/3 studies. Aim: This open-label extension (OLE) stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ea5a3ecb0f8630050930258e17b113e
https://doi.org/10.1183/13993003.congress-2020.4613
https://doi.org/10.1183/13993003.congress-2020.4613
Autor:
Megan S. Rice, Constance H. Katelaris, J. Mark FitzGerald, Siddhesh Kamat, Jorge Maspero, Sivan Harel, Alexandre Jagerschmidt, Asif Khan, Ariel Teper, Neil M.H. Graham, Santiago Quirce, Marcella Ruddy, Bradley E. Chipps, Paul Rowe, Linda B. Ford, Nicola A. Hanania, Gianluca Pirozzi, Yufang Lu, Jonathan Corren, William W. Busse, Nikhil Amin
Publikováno v:
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
Background: Comorbid perennial allergic rhinitis (PAR) or year-round aeroallergen sensitivity substantially contributes to disease burden in patients with asthma. Dupilumab blocks the shared receptor for interleukin (IL) 4 and IL-13, key drivers of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05783e9886c5b4d80cc15e97a8d0808c
https://biblio.ugent.be/publication/8747028/file/8758910
https://biblio.ugent.be/publication/8747028/file/8758910
Autor:
Jorge Maspero, Gianluca Pirozzi, Ariel Teper, Laurent Eckert, Alberto Papi, Neil M.H. Graham, Bingzhi Zhang, Nikhil Amin, Heribert Staudinger, Jingdong Chao, Linda B. Ford, Klaus F. Rabe, Sally E. Wenzel, Bolanle Akinlade, Ian D. Pavord, William W. Busse
Publikováno v:
Advances in Therapy
Introduction Dupilumab, a fully human anti-IL-4Rα monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cffbfa5b78f12d1ec97e1bcdd2cc8c29
https://doi.org/10.1007/s12325-018-0702-4
https://doi.org/10.1007/s12325-018-0702-4